Literature DB >> 1331309

Patterns of serological markers in transfusion-transmitted hepatitis C virus infection using second-generation HCV assays.

P N Lelie1, H T Cuypers, H W Reesink, C L van der Poel, I Winkel, E Bakker, P J van Exel-Oehlers, D Vallari, J P Allain, L Mimms.   

Abstract

A semiautomated dot blot assay and cDNA polymerase chain reaction (PCR) were used to study longitudinal anti-hepatitis C virus (HCV) recognition patterns in relation to presence of HCV-RNA in transfusion recipients and their infectious donors. In 9 recipients, 4 different patterns of HCV infection were observed: (A) persistent HCV carriage accompanied by chronic hepatitis in 6, (B) acute resolved hepatitis, but persistent HCV replication in one, and (C) continuous HCV replication without hepatitis in one and (D) acute resolved hepatitis with clearance of infection in one. This last self-limited infection was characterized by the disappearance of HCV-RNA as well as anti-HCV reactivity. In contrast, antibody reactivity persisted in 7 of 8 patients with chronic HCV infection who could be followed until 1990. Seven of the 9 recipients developed antibodies to all recombinant peptides in dot blot assay; one became positive for anti-C33 and anti-core and one developed anti-core only. The sequence of appearance of antibodies differed among individual patients. In 7 patients with full anti-HCV recognition patterns, the sequence of events was (mean and limits in days after transfusion): onset of hepatitis at day 50 (22-74), seroconversion of anti-C33 at day 91 (59-129), anti-core at day 133 (54-203), and anti-C100 at day 143 (59-365). The incorporation of C33 and core proteins, in addition to C100, in the second generation anti-HCV ELISA enhanced the detection rate in the HCV-infected transfusion recipients from 7/9 (78%) to 9/9 (100%).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1331309     DOI: 10.1002/jmv.1890370310

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  16 in total

Review 1.  Hepatitis C in childhood.

Authors:  F Bortolotti
Journal:  Indian J Pediatr       Date:  1995 Sep-Oct       Impact factor: 1.967

2.  Blood screening by nucleic acid amplification technology: current issues, future challenges.

Authors:  J L Gallarda; E Dragon
Journal:  Mol Diagn       Date:  2000-03

3.  Definition of false-positive reactions in screening for hepatitis C virus antibodies.

Authors:  M Schröter; H H Feucht; P Schäfer; B Zöllner; S Polywka; R Laufs
Journal:  J Clin Microbiol       Date:  1999-01       Impact factor: 5.948

Review 4.  Mode of hepatitis C virus infection, epidemiology, and chronicity rate in the general population and risk groups.

Authors:  H L Tillmann; M P Manns
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

5.  Mapping of serotype-specific, immunodominant epitopes in the NS-4 region of hepatitis C virus (HCV): use of type-specific peptides to serologically differentiate infections with HCV types 1, 2, and 3.

Authors:  P Simmonds; K A Rose; S Graham; S W Chan; F McOmish; B C Dow; E A Follett; P L Yap; H Marsden
Journal:  J Clin Microbiol       Date:  1993-06       Impact factor: 5.948

6.  Study on reliability of commercially available hepatitis C virus antibody tests.

Authors:  H H Feucht; B Zöllner; S Polywka; R Laufs
Journal:  J Clin Microbiol       Date:  1995-03       Impact factor: 5.948

7.  Storage conditions of blood samples and primer selection affect the yield of cDNA polymerase chain reaction products of hepatitis C virus.

Authors:  H T Cuypers; D Bresters; I N Winkel; H W Reesink; A J Weiner; M Houghton; C L van der Poel; P N Lelie
Journal:  J Clin Microbiol       Date:  1992-12       Impact factor: 5.948

8.  Multispecific T cell response and negative HCV RNA tests during acute HCV infection are early prognostic factors of spontaneous clearance.

Authors:  E Spada; A Mele; A Berton; L Ruggeri; L Ferrigno; A R Garbuglia; M P Perrone; G Girelli; P Del Porto; E Piccolella; M U Mondelli; P Amoroso; R Cortese; A Nicosia; A Vitelli; A Folgori
Journal:  Gut       Date:  2004-11       Impact factor: 23.059

9.  Peptide based enzyme immunoassays for detecting hepatitis C antibodies in sera of people at high risk.

Authors:  F G Gabriel; C G Teo
Journal:  J Clin Pathol       Date:  1994-04       Impact factor: 3.411

10.  Risk of liver disease in HCV-seropositive kidney transplant recipients.

Authors:  M S Rohr; R R Lesniewski; C A Rubin; R G Johnson; E R Heise; J C McDonald; P L Adams
Journal:  Ann Surg       Date:  1993-05       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.